Pyridostigmine Bromide

Phase 2Small molecule

JJames J. Peters Veterans Affairs Medical Center

Pyridostigmine Bromide is one of 192 small molecule programs targeting Orthostatic Hypotension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

191

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic HypotensionActive, not recruiting

Parkinson DiseaseActive, not recruiting

Heart FailureActive, not recruiting

Spinal Muscular AtrophyActive, not recruiting

Pompe DiseaseActive, not recruiting

Chronic Fatigue SyndromeActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Orthostatic HypotensionPhase 2

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Heart FailurePhase 2

Active, not recruiting

Spinal Muscular AtrophyPhase 2

Active, not recruiting

Pompe DiseasePhase 1

Active, not recruiting

Chronic Fatigue SyndromePhase 2

Active, not recruiting

Spinal Cord InjuryPhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Pyridostigmine Bromide

JJames J. Peters Veterans Affairs Medical Center

Phase 2

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

LCZ696

Novartis

Preclinical

15 6

Zemplar

Activase

Coumadin

1 9

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Efficacy and Safety

NCT05334485

Phase 2Recruiting

Parkinson Disease

NCT05603715

Clinical

Trials by Indication[1]

Orthostatic Hypotension3 trials

Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study

Completed·SSeoul National University Hospital·Phase 4·NCT02308124·87 enrolled

Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI

Completed·JJames J. Peters Veterans Affairs Medical Center·Phase 2·NCT02307526·10 enrolled

Treatment of Orthostatic Hypotension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223691·389 enrolled

Parkinson disease1 trial

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Recruiting·UUniversity of Vermont Medical Center·Phase 2·NCT05603715·16 enrolled

Spinal Cord Injury1 trial

The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury

Completed·JJames J. Peters Veterans Affairs Medical Center·Phase 2·NCT02893553·21 enrolled

Spinal Muscular Atrophy1 trial

Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3

Completed·—·Phase 2·NCT02227823·4 enrolled

SARS CoV 2 Infection1 trial

Pyridostigmine in Severe SARS-CoV-2 Infection

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2/3·NCT04343963·436 enrolled

6 more indications

Chronic Fatigue Syndrome1 trial

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Completed·—·Phase 2·NCT03674541·45 enrolled

HIV1 trial

Pyridostigmine as Immunomodulator in People Living With HIV

Suspended·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT03312244·60 enrolled

Efficacy and Safety1 trial

Pyridostigmine Efficacy and Safety for Treatment of Ileus After Colorectal Surgery

Recruiting·—·Phase 2/3·NCT05334485·50 enrolled

Gastrointestinal Dysfunction1 trial

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

Completed·CChristian Baumann·Phase 2·NCT01993680·18 enrolled

Pompe Disease1 trial

A Pilot Study of Pyridostigmine in Pompe Disease

Terminated·UUniversity of Florida·Phase 1·NCT02357225·2 enrolled

Heart Failure1 trial

Safety Study of Pyridostigmine in Heart Failure

Completed·NNYU Langone Health·Phase 2·NCT01415921·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Pyridostigmine Bromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pyridostigmine Bromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pyridostigmine Bromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — James J. Peters Veterans Affairs Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJames J. Peters Veterans Affairs Medical Center

Pyridostigmine Bromide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Orthostatic Hypotension3 trials

Parkinson disease1 trial

Spinal Cord Injury1 trial

Spinal Muscular Atrophy1 trial

SARS CoV 2 Infection1 trial

Chronic Fatigue Syndrome1 trial

HIV1 trial

Efficacy and Safety1 trial

Gastrointestinal Dysfunction1 trial

Pompe Disease1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News